Claudia Canzonetta

Claudia Canzonetta

Auto-generated profile, based on publicly available information

Claudia Canzonetta

Immunology Area, Pediatric Hospital Bambino Gesù, Rome, Italy

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in Cell
Verified
Journal Article
Closed access
VPVania Parelho
Vania Parelho
SHSuzana Hadjur
Suzana Hadjur
MSMikhail Spivakov
Mikhail Spivakov
MLMarion Leleu
Marion Leleu
SSStephan Sauer
Stephan Sauer
MMMatthias Merkenschlager
Matthias Merkenschlager

1 September 2008 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
CCClaudia Canzonetta
Claudia Canzonetta
CMClaire Mulligan
Claire Mulligan
SDSamuel Deutsch
Samuel Deutsch
SRSandra Ruf
Sandra Ruf
AOAideen O'DOherty
Aideen O'DOherty
DNDean Nizetic
Dean Nizetic

1 April 2005 in EMBO Reports
Verified
Journal Article
Open access
PDF file
CCCheok‐Man Chow
Cheok‐Man Chow
AGAndrew Georgiou
Andrew Georgiou
HSHenrietta Szutorisz
Henrietta Szutorisz
ASAlexandra Maia e Silva
Alexandra Maia e Silva
APAna Pombo
Ana Pombo
NDNiall Dillon
Niall Dillon
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

27 March 2005 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
HSHenrietta Szutorisz
Henrietta Szutorisz
CCClaudia Canzonetta
Claudia Canzonetta
AGAndrew Georgiou
Andrew Georgiou
CCCheok-Man Chow
Cheok-Man Chow
Laszlo ToraLaszlo Tora
Laszlo Tora
NDNiall Dillon
Niall Dillon
The differentiation potential of stem cells is determined by the ability of these cells to establish and maintain developmentally regulated gene expression programs that are specific to different lineages. Although transcriptionally potentiated epigenetic states of genes have been described for haematopoietic progenitors, the developmental stage at which the formation of lineage-specific gene expression domains is initiated remains unclear. In this study, we show that an intergenic cis-acting element in the mouse λ5-VpreB1 locus is marked by histone H3 acetylation and histone H3 lysine 4 methylation at a discrete site in embryonic stem (ES) cells. The epigenetic modifications spread from this site toward the VpreB1 and λ5 genes at later stages of B-cell development, and a large, active chromatin domain is established in pre-B cells when the genes are fully expressed. In early B-cell progenitors, the binding of haematopoietic factor PU.1 coincides with the expansion of the marked region, and the region becomes a center for the recruitment of general transcription factors and RNA polymerase II. In pre-B cells, E2A also binds to the locus, and general transcription factors are distributed across the active domain, including the gene promoters and the intergenic region. These results suggest that localized epigenetic marking is important for establishing the transcriptional competence of the λ5 and VpreB1 genes as early as the pluripotent ES cell stage.

1 January 2019 in Immunology Letters
Verified
Journal Article
Closed access
EFE. Ferretti
E. Ferretti
AHA.L. Horenstein
A.L. Horenstein
CCC. Canzonetta
C. Canzonetta
FCFederica Costa
Federica Costa
FMFabio Morandi
Fabio Morandi

21 May 2015 in Stem Cells
Verified
Journal Article
Open access
PDF file
AMAoife Murray
Aoife Murray
ALAudrey Letourneau
Audrey Letourneau
CCClaudia Canzonetta
Claudia Canzonetta
ESElisavet Stathaki
Elisavet Stathaki
SGStefania Gimelli
Stefania Gimelli
DNDean Nizetic
Dean Nizetic
Trisomy 21 (T21), Down Syndrome (DS) is the most common genetic cause of dementia and intellectual disability. Modeling DS is beginning to yield pharmaceutical therapeutic interventions for amelioration of intellectual disability, which are currently being tested in clinical trials. DS is also a unique genetic system for investigation of pathological and protective mechanisms for accelerated ageing, neurodegeneration, dementia, cancer, and other important common diseases. New drugs could be identified and disease mechanisms better understood by establishment of well-controlled cell model systems. We have developed a first nonintegration-reprogrammed isogenic human induced pluripotent stem cell (iPSC) model of DS by reprogramming the skin fibroblasts from an adult individual with constitutional mosaicism for DS and separately cloning multiple isogenic T21 and euploid (D21) iPSC lines. Our model shows a very low number of reprogramming rearrangements as assessed by a high-resolution whole genome CGH-array hybridization, and it reproduces several cellular pathologies seen in primary human DS cells, as assessed by automated high-content microscopic analysis. Early differentiation shows an imbalance of the lineage-specific stem/progenitor cell compartments: T21 causes slower proliferation of neural and faster expansion of hematopoietic lineage. T21 iPSC-derived neurons show increased production of amyloid peptide-containing material, a decrease in mitochondrial membrane potential, and an increased number and abnormal appearance of mitochondria. Finally, T21-derived neurons show significantly higher number of DNA double-strand breaks than isogenic D21 controls. Our fully isogenic system therefore opens possibilities for modeling mechanisms of developmental, accelerated ageing, and neurodegenerative pathologies caused by T21. Stem Cells 2015;33:2077–2084 Video Highlight: https://youtu.be/MoMwXg2azGo